Clinical trials: FDC
Healthy Subjects
A Pharmacokinetic Study of SID1903 (FDC of Dapagliflozin and Sitagliptin) in Healthy Adult Volunteers
This study is to compare and evaluate the safety and pharmacokinetic characteristics (PK) after administration of SID1903 and SID1903-R1/SID1903-R2 in healthy adult volunteers.
- Trial name
- NCT05236998
- Testing
- SID1903 (FDC), Dapagliflozin and Sitagliptin
- Where
- South Korea
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- SK Chemicals Co., Ltd.
Pulmonary Disease, Chronic Obstructive
Long-term Use of Spiolto Respimat in Japanese Patients With Chronic Obstructive Pulmonary Disease
Study to assess the long-term safety and effectiveness of Spiolto in Japanese patients with Chronic Obstructive Pulmonary Disease (COPD) in real-world setting
- Trial name
- NCT02850978
- Testing
- Spiolto
- Where
- Japan
- Volunteers
- 1,335 people
- Sponsor
- Boehringer Ingelheim
Advanced Non-Small Cell Lung Cancer
A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
This study is researching an experimental drug called fianlimab (also called REGN3767), combined with a medication called cemiplimab (also called REGN2810), individually called a "study drug" or collectively called "study drugs".
- Trial name
- NCT05785767
- Testing
- fianlimab, cemiplimab
- Where
- 106 sites in United States, Australia and 9 more
- Volunteers
- 149 people
- Sponsor
- Regeneron Pharmaceuticals
Advanced Solid Tumors
A Study of EMB-02 in Participants With Advanced Solid Tumors
The primary purpose of this study is to identify the recommended Phase 2 dose(s) (RP2Ds) and schedule assessed to be safe for EMB-02 and to characterize the safety and tolerability of EMB-02 at the RP2Ds.
- Trial name
- NCT04618393
- Testing
- EMB-02
- Where
- 10 sites in United States, Australia and 1 more
- Volunteers
- 47 people
- Sponsor
- Shanghai EpimAb Biotherapeutics Co., Ltd.
Hypertension
A Study Investigating the Bioequivalence of the Fixed Dose Combination of COREG CR to COREG CR and ZESTRIL.
This study will be a randomized study investigating the bioequivalence of COREG CR to its components, COREG and Lisinopril (ZESTRIL).
- Trial name
- NCT00552708
- Testing
- COREG CR, Lisinopril
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HER2-positive Breast Cancer
An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic
This single arm, multicenter study provides the pertuzumab and trastuzumab fixed-dose combination formulation for subcutaneous injection (PH FDC SC) administered at home by a home health nursing provider for patients with human…
- Trial name
- NCT04395508
- Testing
- Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC)
- Where
- 12 sites in United States
- Sponsor
- Genentech, Inc.
Healthy
Empa/Lina FDC Food Effect Study (Japan)
The trial will be performed as an open-label, randomised, single-dose, two-sequence crossover design for the assessment of effect of food on bioavailability of empagliflozin / linagliptin fixed dose combination (FDC) tablet.
- Trial name
- NCT02815644
- Testing
- empagliflozin/linagliptin FDC
- Where
- Japan
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
HIV-1 Infection
Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults
The primary objective of this study is to evaluate the efficacy of switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) relative to continuing on a baseline regimen…
- Trial name
- NCT02605954
- Testing
- E/C/F/TAF, ABC/3TC, Third Antiretroviral Agent
- Where
- 49 sites in United States, France and 4 more
- Volunteers
- 275 people
- Sponsor
- Gilead Sciences
Advanced Cancer
An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread
The purpose of this study is to demonstrate the safety and preliminary activity with triple combinations of relatlimab in combination with nivolumab and BMS-986205, or in combination with nivolumab and ipilimumab in…
- Trial name
- NCT03459222
- Testing
- Relatlimab, Nivolumab, BMS-986205
- Where
- 22 sites in United States, Australia and 5 more
- Volunteers
- 229 people
- Sponsor
- Bristol-Myers Squibb
FDC, Diabetes Mellitus, Type 2
To Compare the Pharmacokinetic Characteristics of the Fixed-dose Combination Compared to the Loose Combination
To compare the safety and pharmacokinetic properties between the administration of DWP16001 and DWC202213 as an individual drug, and the administration of DWJ1563 as a combination drug.
- Trial name
- NCT05737771
- Testing
- DWC202213, DWJ1563, DWP16001
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Pulmonary Disease, Chronic Obstructive
Cardiovascular Function in COPD Patients
The objectives of the study are to explore the effect of treatment with tiotropium + olodaterol fixed dose combination (FDC) compared to fluticasone propionate + salmeterol FDC on: reversal of left ventricular diastolic…
- Trial name
- NCT03055988
- Testing
- Tiotropium, Olodaterol, Fluticasone propionate
- Where
- 10 sites in Germany
- Volunteers
- 76 people
- Sponsor
- Boehringer Ingelheim
Healthy Subjects
A Pharmacokinetic Study of SID1903 (FDC of Dapagliflozin and Sitagliptin) in Healthy Adult Volunteers
This study is to compare and evaluate the safety and pharmacokinetic characteristics (PK) after administration of SID1903 and SID1903-R1/SID1903-R2 in healthy adult volunteers.
- Trial name
- NCT05453786
- Testing
- SID1903, SID1903-R1/SID1903-R2
- Where
- South Korea
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- SK Chemicals Co., Ltd.